There is no question that when it comes to testing for COVID-19, the U.S. government has fallen short. Abbott has received authorization from the U.S. Food and Drug Administration (FDA) for the detection of novel coronavirus (COVID-19) using the fastest available molecular point-of-care test.

What makes this lab device so innovative is its ability to be used in non-traditional places. Abbott ID NOW is a lightweight box, 6.6 pounds (3 kg), and the size of a small toaster, that processes the new Abbott ID NOW COVID-19 test while delivering positive results in as little as five minutes and negative results in 13 minutes.

Abbott claims that ID NOW, when combined with the Abbott RealTime SARS-CoV-2 EUA test running on an m2000 RealTime molecular system, will produce about 5 million tests in April.